NCT02049450View on ClinicalTrials.gov

Study of Efficacy and Safety of INC424 in Regularly Transfused Patients With Thalassemia.

PHASE2CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

May 28, 2014

Primary Completion Date

April 12, 2016

Study Completion Date

April 12, 2016

Conditions
Thalassemia Major
Interventions
DRUG

ruxolitinib

Ruxolitinib was taken at a starting dose of 10 mg twice daily with dose adjustments within the range of 5 to 25 mg twice daily.

Trial Locations (7)

10700

Novartis Investigative Site, Bangkok

20122

Novartis Investigative Site, Milan

34093

Novartis Investigative Site, Istanbul

35040

Novartis Investigative Site, Izmir

90146

Novartis Investigative Site, Palermo

GR-115 27

Novartis Investigative Site, Athens

1107 2020

Novartis Investigative Site, Beirut

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY